Notably, treatment with the B1R ligand Lys-des(Arg(9))-bradykinin (LDBK) or bradykinin failed to increase the expression of ICAM-1, VCAM-1, or PD-L1 in the B1R-OE GBM cells (Figure 2C). Here, ICAM1 is linked to glioblastoma.